Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 5Thoracic 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1

Conditions

Myelodysplastic Syndromes 1Leukemia 1

Interventions

Cyclophosphamide 49fludarabine phosphate 42fludarabine 37Azacitidine 35Busulfan 30Whole-Body Irradiation 26Imatinib Mesylate 24Antilymphocyte Serum 24Tacrolimus 23Mycophenolic Acid 22Cytarabine 21Filgrastim 20Peripheral Blood Stem Cell Transplantation 17Methotrexate 17Melphalan 17Cyclosporine 16venetoclax 14thymoglobulin 14Granulocyte Colony-Stimulating Factor 14Thiotepa 12ruxolitinib 11Stem Cell Transplantation 11Decitabine 11Dasatinib 11Alemtuzumab 11nilotinib 10Radiotherapy 10Rituximab 9Cord Blood Stem Cell Transplantation 9ponatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Darbepoetin alfa × Myeloid × Clear all
NCT01222195 2012-08-07

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

M.D. Anderson Cancer Center

Phase 2 Terminated
1 enrolled 5 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡